PD98059

For research use only.

Catalog No.S1177

261 publications

PD98059 Chemical Structure

Molecular Weight(MW): 267.28

PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2. PD98059 is a ligand for the aryl hydrocarbon receptor (AHR) and functions as an AHR antagonist.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 134 In stock
USD 147 In stock
USD 470 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's PD98059 has been cited by 261 publications

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2. PD98059 is a ligand for the aryl hydrocarbon receptor (AHR) and functions as an AHR antagonist.
Features Does not inhibit c-Raf phosphorylated MEK1.
Targets
MEK1 [1]
(Cell-free assay)
2 μM
In vitro

PD98059 inhibits either basal MEK1 or a partially activated MEK produced by mutation of serine at residues 218 and 222 to glutamate (MEK-2E) with IC50 of 2 μM. PD98059 does not inhibit the MAPK homologues JNK and P38. PD98059 is highly selective against MEK, as it does not inhibit a number of other kinase activities including Raf kinase, cAMP-dependent kinase, protein kinase C, v-Src, epidermal growth factor (EGF) receptor kinase, insulin receptor kinase, PDGF receptor kinase, and phosphatidylinositol 3-kinase. PD98059 inhibits PDGF-stimulated activation of MAPK and thymidine incorporation into 3T3 cells with IC50 of ~10 μM and ~7 μM, respectively. [1] PD98059 potently prevents the activation of MEK1 by Raf or MEK kinase with IC50 of 4 μM, and weakly inhibits the activation of MEK2 by Raf with IC50 of 50 μM. PD98059 does not inhibit the activation of MEK homologues MKK4 and RK kinase that participate in stress and interleukin-1-stimulated kinase cascades in KB and PC12 cells, and the activation of p70 S6 kinase by insulin or epidermal growth factor in Swiss 3T3 cells. [2] PD98059 completely blocks the nerve growth factor (NGF)-induced differentiation of PC12 cells without altering cell viability. [3] PD98059 inhibits the proliferation of RAW264.7 cells in the culture containing RANKL in a dose-dependent manner, resulting in an apparent decrease of TRAP-positive cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
H1355 NXPpfYJGTnWwY4Tpc44hSXO|YYm= MUGyOUDPxE1? NInLU3MyKGh? MnLwZox2dnS|IITo[UBDY2GfUD3pcoR2[2WmIHnuZ5Jm[XOnIHnuJJBpd3OyaH:tR4hsOSCjbnSgdIhwe3Cqbz3FVmsh\XiycnXzd4lwdg>? NWXUdm5tOjV5NkmxPFE>
MCF-7  NX\xfoYxTnWwY4Tpc44hSXO|YYm= MW[xNEDPxE1? MVuxJIg> Ml3JbY5pcWKrdIOgTWwuOThvZX7oZY5k\WRiY3XscEBucWe{YYTpc44> MXOyOVczPzBzMR?=
HepG2  MVHGeY5kfGmxbjDBd5NigQ>? NWjXSYtPOTBizszN M{jMVlUhcA>? MYXicI9kc3NicHjvd5Bpd3K7bHH0[YQhVUGSS4OgbY5lfWOnZDDifUBmgG:pZX7veZMhXEeILd8yNS=> MnjhNlU2PjB2OEi=
HepG2  M3\xT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;TXFFzOjBizszN M{XqNlI1KGh? MUfzeZBxemW|c3XzJHRITi4QskGtbY5lfWOnZDDj[YxtKHC{b3zp[oVz[XSrb36gZY5lKGmwdnHzbY9v MXKyOVU3ODR6OB?=
MDA-MB-231 MXvGeY5kfGmxbjDBd5NigQ>? MkjPNlUh|ryP M4L1WFIuOyCq NY[ySpFp\GWlcnXhd4V{KHBvRWLLNU8zKGGwZDDTNVAxSTRiZYjwdoV{e2mxbh?= M1zNU|I2PTV3OEe1
SW480 MmLSSpVv[3Srb36gRZN{[Xl? M3nKclIxyqEQvF2= NFTBXZYyyqCq NF\4SIhz\WS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGFVTjNicILveIVqdg>? M{TFNFI2PDR5OEG2
HCT-15 NFzpcJhHfW6ldHnvckBCe3OjeR?= MWSxJIg> NWP2SWdI[XS2ZX71ZZRmeyCSR1WyMYlv\HWlZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJGVzc8Li MV:yOVQ{OTR{NR?=
HCT-15 MWLBdI9xfG:|aYOgRZN{[Xl? M3fMUVEhcA>? MXPhZo9tcXOqZYOgeIhmKHC{b4TlZ5RqfmViZX\m[YN1eyCxZjDQS2UzyqCjZ3HpcpN1KGO3cnP1cYlvNWmwZIXj[YQh[XCxcITvd4l{ NGLyRm4zPTR|MUSyOS=>
786-O MnXHRZBweHSxc3nzJGF{e2G7 NYHKVXZRPTEEoN88US=> MWqyOEBp M1:2[pBwfGWwdHnheIV{yqC2aHWgdJJwNWGyb4D0c5Rq[yCnZn\lZ5R{KG:oIF7D M{Lkd|I1PTB6NEe2
A498 MVfBdI9xfG:|aYOgRZN{[Xl? Mme1OVDDqM7:TR?= NEnqXJUzPCCq M2TsSpBwfGWwdHnheIV{yqC2aHWgdJJwNWGyb4D0c5Rq[yCnZn\lZ5R{KG:oIF7D MV:yOFUxQDR5Nh?=
NHBE NGnkRmlHfW6ldHnvckBCe3OjeR?= MnS3Nk8zOCEQvF2= M{D4bVIhcA>? MVjheJRmdnWjdHXzJGlNNTN|IIP0bY12dGG2ZXSgR3hEVDhxSVytPEB{\WO{ZYTpc44> MXeyOFQ4QTV{Nh?=
A375 M{TufGNmdGxiSX72ZZNqd25iQYPzZZk> NHj6NngyOOLCk{KwJOK2VQ>? M4DFWlI1KGh? M3zzOZJm\HWlZYOgcYVt[W6xbXGgZ4VtdCCrbo\hd4lwdg>? NWjoRnlHOjR2Nk[wN|Y>
HBMEC Mo\hSpVv[3Srb36gRZN{[Xl? MmjtNVAh|ryP NHzQ[WwyKGh? NEXL[oJjdG:la4OgWmVITi2rbnT1Z4VlKEWyaFGyJIV5eHKnc4Ppc44> NEHM[5EzPDR3OEm4Ni=>
HPAEpiCs  Mlf4SpVv[3Srb36gRZN{[Xl? MYKzNEDPxE1? MoHONUBp MYDpcohq[mm2czDUUmYu|rFic4TpcZVt[XSnZDDwOFIweDR2IF3BVGsheGixc4Doc5J6dGG2aX;u NYP6dVBvOjR2NEG4O|A>
BeWo NH;LVY9HfW6ldHnvckBCe3OjeR?= MoHFNVDDqM7:TR?= MYGyJIg> MkjXbY5pcWKrdIOgSXJMOS9{ NXL6Wm12OjR2M{O4OFY>
PC3  MnrGRZBweHSxc3nzJGF{e2G7 NX:3e4FbPTBizszN MWqwMlUhcA>? MYfpcohq[mm2czDNTHkuPDR7LXnu[JVk\WRiYYDvdJRwe2m|wrC= M1zRNVI1PDJ2OEi5
HGC-27 M{PaPWFxd3C2b4Ppd{BCe3OjeR?= NVPIdnVsOSEEtV2= MYKxJIg> NXHaU2Nue3WycILld5NmeyCUQVSwNFEheGy3czDNT{0zOjB4LXnu[JVk\WRiY3XscEB3cWGkaXzpeJkhdG:|cx?= NWm4eJZYOjR2MU[zOFk>
MCF-7 M4jPRWZ2dmO2aX;uJGF{e2G7 NGOxdGcyOMLizszN NU\FW4xyOTBxM{CgcYlv NFTRXpZz\WS3Y3XzJJRp\SCXVGCt[IVx\W6mZX70JGVTUyCyaH;zdIhwenmuYYTpc44> NG\tXo0zPDN7MEixPS=>
HUVECs NWPSeVRETnWwY4Tpc44hSXO|YYm= NIrLRXEyOMLizszN NHS0O5AyKGh? MnuzbY5pcWKrdIOgeIhmKEiGTDDy[YR2[2WmIFPPXE0zKGW6cILld5Nqd25iYX7kJHBIUS1{IILlcIVie2V? NWT0VXd3OjR|OEWxNFk>
HeLa MlrvSpVv[3Srb36gRZN{[Xl? NVvRcmZbPTBizszN MVmwMlUhcA>? NETyNVFjdG:la4OgWHJZNTFiboXjcIVieiCvaXfyZZRqd25iYX7kJHRZVkmSIHTve44uemWpdXzheIlwdg>? NEfwTVUzPDN5NkiyOy=>
HL-60  M1\HWWZ2dmO2aX;uJGF{e2G7 NXjCTJBTOTBxMkCg{txO MVqxJIg> NH\zSHpqdmirYnn0d{B1cGYEoF6uJINpcW6nboPpd4V5fHKjY4VCpIlv\HWlZXSg[Iln\mW{ZX70bYF1cW:wIHnueI8h\3KjboXsc4N6fGW| NFj5VW8zPDN3N{CyNC=>
HL-60 NWnwfll5TnWwY4Tpc44hSXO|YYm= MV[yJOK2VQ>? MmCxNVYhcA>? M2rFc2ROW09? M3\idIlvcGmkaYTzJJRp\SCjc4PvZ4lifGmxbjDv[kBxWzZ{MTDSZYYuOSCjbnSgUmZCXGN|LDDhcoQhfGinIGLBMYlv\HWlZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJI52[2ynYYKgUmZCXGN| NHvoeoQzPDN|MEC2PC=>
HEK 293 M2LhdmZ2dmO2aX;uJGF{e2G7 MYqxNEDPxE1? M{HoPVUhcA>? Mn\USG1UVw>? NWDxZWdicW6qaXLpeJMhX262LXnu[JVk\WRizsKtZ4F1\W6rbj;UR2Y1KGGldHn2bZR6KGGwZDDueYNt\WG{IN8yMYNifGWwaX6gZYNkfW23bHH0bY9v NXXaRYkxOjR|MkSzOlY>
HEK 293 MXHGeY5kfGmxbjDBd5NigQ>? MVSxNEDPxE1? NXK2Wml7PSCq M4GzU2ROW09? MYXzeZBxemW|c3XzJJRp\SCFUmSgZYN1cX[rdIm= NFrLRWozPDN{NEO2Oi=>
SW480 MXrGeY5kfGmxbjDBd5NigQ>? MnTnNVAh|ryP M{K0cVIxKGh? NUjM[3k4TE2VTx?= MoXCd5VxeHKnc4Pld{B1cGViQ2LUJIFkfGm4aYT5 M1HNNlI1OzJ2M{[2
HCSMCs NGXKcopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;5NVAh|ryP NFnMd5IzPCCq NYL5[nFZ[myxY3vzJGZCSlB2LXnu[JVk\WRiSFPBV21EKHC{b3zp[oVz[XSrb36= NUjkTIZQOjR|MUKzPFE>
PANC-1 M{\qV2Z2dmO2aX;uJGF{e2G7 NWPkZnJ1OjBizszN NIPKd4Y1QCCq MlvNbY5pcWKrdIOgeIhmKGW6cILld5Nqd25ib3[g{rQ3TCCrbjDy[ZNxd26|ZTD0c{B1cGViUGDBVu61yqCjZ3;ubZN1yqB? NIrBbVAzPDJ7NEGzNy=>
A549 NWHWXFhFTnWwY4Tpc44hSXO|YYm= NWHMSmlpOzBizszN NGC1SmIxNjViaB?= MXHEUXNQ M3fzfolvcGmkaYTzJJRp\SC2aILvcYJqdi2rbnT1Z4VlKEmOLUivR3hEVDhvTIXjJIFkfGm4aYT5 NEK5VGQzPDJ5N{[5Oi=>
A549 NHryR2dHfW6ldHnvckBCe3OjeR?= MlPkN|Ah|ryP NUnwcI5JOC53IHi= NFPMT5BFVVOR MoXYbY5pcWKrdIOgeIhzd22kaX6tbY5lfWOnZDDDM2VDWM7{IGTodlI{PcLicHjvd5Bpd3K7bHH0bY9v M1\selI1Ojd5Nkm2
MC-3 NFXHPItCeG:ydH;zbZMhSXO|YYm= M4PyflExKM7:TR?= NF;qXYozPCCq MlvsdI91\W62aXH0[YQhVUWVQz3pcoR2[2WmIHHwc5B1d3OrczDpckAh[2WubIO= M{PTR|I1OjdyNUKz
Raji  NW\H[GRyTnWwY4Tpc44hSXO|YYm= NHn4RVMyOCEQvF2= M1zq[|EhcA>? M3fuWIJtd2OtczDod2JCTkZiaX7keYNm\CCHcnuxM|IheGixc4Doc5J6dGG2aX;u MmjTNlQzPjl4M{C=
Raji  NEXBcFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUf0ZWF6OTBizszN NXHkWYVXOSCq NUXMWoZycW6qaXLpeJMhfGinIHLhd4FtKG:{IHjzRmFHTi2|dHnteYxifGWmIHPlcIwheHKxbHnm[ZJifGmxbjDhcoQhfmmjYnnsbZR6 M{SyfVI1OjZ7NkOw
HT29 M{Pse2Z2dmO2aX;uJGF{e2G7 MWmxNEDPxE1? Mnr5NkBp M4nJT4lvcGmkaYTzJI9nKEqDS{KsJGVTUzFxMjDhcoQhW1SDVEOgdIhwe3Cqb4L5cIF1cW:w MX6yOFI3PTJ7Mx?=
HepG2 NH7TO2NCeG:ydH;zbZMhSXO|YYm= MmfINlAh|ryP MnrONlQhcA>? M{HPTolvcGmkaYTzJGVTUzFxMjDwbI9{eGixconsZZRqd25iYX7kJIVvcGGwY3XzJHZDOS2rbnT1Z4VlKGGyb4D0c5Nqew>? NEHGXZkzPDJ2N{mwPS=>
HepG2 NYLYcmQ2TnWwY4Tpc44hSXO|YYm= MmHSNlAh|ryP NHLhdmEzKGh? MoXF[Y5p[W6lZYOgWmIyNWmwZIXj[YQhTk:[T{PhJJRz[W6|Y4LpdJRqd26jbDDhZ5Rqfmm2eR?= MVyyOFI1PzlyOR?=
TE4 M{iz[mZ2dmO2aX;uJGF{e2G7 NEPKT|UzOC93MD:xNFAh|ryP NWHpeWhnPDhiaB?= MmHOSG1UVw>? M3v5VolvcGmkaYTzJJAuTXKtIHHu[EB4d3K2bXHucolvKGSxd37y[Yd2dGG2ZXSgdE1Cc3RiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NIPGWGwzPDJ2NECyNy=>
TE1 MV;GeY5kfGmxbjDBd5NigQ>? NET6fGQzOC93MD:xNFAh|ryP NYm5RXpDPDhiaB?= M4m1eGROW09? NFzVe49qdmirYnn0d{BxNUW{azDhcoQhf2:{dH3hco5qdiCmb4fudoVofWyjdHXkJJAuSWu2IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MoHtNlQzPDRyMkO=
KYSE30 M4CxbGZ2dmO2aX;uJGF{e2G7 NYLMc4VYOjBxNUCvNVAxKM7:TR?= M170RVQ5KGh? NI\3cINFVVOR MYDpcohq[mm2czDwMWVzcyCjbnSge49zfG2jbn7pckBld3ewcnXneYxifGWmIICtRYt1KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MkH3NlQzPDRyMkO=
TE1 NX;wW4Y{TnWwY4Tpc44hSXO|YYm= NVLOUlRuPTBizszN MnOxOFghcA>? NX22VnRKTE2VTx?= MkT2eZBz\We3bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhUEyDIHPsZZN{KEl? NI\zOnYzPDJ2NECyNy=>
TE3 NX7YZWhPTnWwY4Tpc44hSXO|YYm= MoPkOVAh|ryP NFnIO3A1QCCq MVTEUXNQ NVzwUnlkfXC{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSFzBJINt[XO|IFm= NIXmZW0zPDJ2NECyNy=>
TE4 M2rxd2Z2dmO2aX;uJGF{e2G7 NULCOZJwPTBizszN MVq0PEBp MoHJSG1UVw>? MYj1dJJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBJVEFiY3zhd5MhUQ>? NYXkS5Z5OjR{NESwNlM>
TE5 NEPNSlJHfW6ldHnvckBCe3OjeR?= Mn\JOVAh|ryP NXvjSFA2PDhiaB?= NVixSoZHTE2VTx?= MoPOeZBz\We3bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhUEyDIHPsZZN{KEl? M1Had|I1OjR2MEKz
KYSE30 M4LuSWZ2dmO2aX;uJGF{e2G7 NEXkV4s2OCEQvF2= NYnqW2szPDhiaB?= M2DNZmROW09? NWn2SWRifXC{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSFzBJINt[XO|IFm= NYXSNHJROjR{NESwNlM>
MKN7 M4nvOGZ2dmO2aX;uJGF{e2G7 M1PTd|UxKM7:TR?= NEixUFE1QCCq MWjEUXNQ NFXYRWFqdmO{ZXHz[ZMh\XiycnXzd4lwdiCxZjDIUGEuSTB{IH;yJGhNSS2DMkSgcY9t\WO3bHXz NXrCb3B2OjR{NESwNlM>
OE19 NED0dW1HfW6ldHnvckBCe3OjeR?= NGD3PXo2OCEQvF2= MYm0PEBp M4qxSmROW09? M1Xwfolv[3KnYYPld{BmgHC{ZYPzbY9vKG:oIFjMRU1CODJib4KgTGxCNUF{NDDtc4xm[3WuZYO= MXGyOFI1PDB{Mx?=
KATOIII  MXLGeY5kfGmxbjDBd5NigQ>? NEPGeYw2OCEQvF2= NUjDNGVVPDhiaB?= MnPxSG1UVw>? MnnFbY5kemWjc3XzJIV5eHKnc4Ppc44hd2ZiSFzBMWExOiCxcjDIUGEuSTJ2IH3vcIVkfWyncx?= MorINlQzPDRyMkO=
NCI-N87  MVzGeY5kfGmxbjDBd5NigQ>? NEi3e2Y2OCEQvF2= NUP2XXpCPDhiaB?= MnfqSG1UVw>? NV\MfnRncW6lcnXhd4V{KGW6cILld5Nqd25ib3[gTGxCNUFyMjDvdkBJVEFvQUK0JI1wdGWldXzldy=> Mn\qNlQzPDRyMkO=
NUGC3 M3u1eGZ2dmO2aX;uJGF{e2G7 M4XsTFUxKM7:TR?= MUC0PEBp Mln0SG1UVw>? M1LuWYlv[3KnYYPld{BmgHC{ZYPzbY9vKG:oIFjMRU1CODJib4KgTGxCNUF{NDDtc4xm[3WuZYO= M{L2WFI1OjR2MEKz
NUGC2 NFn1fGRHfW6ldHnvckBCe3OjeR?= MVm1NEDPxE1? NWKyOIo2PDhiaB?= M3XjdmROW09? MnXMbY5kemWjc3XzJIV5eHKnc4Ppc44hd2ZiSFzBMWExOiCxcjDIUGEuSTJ2IH3vcIVkfWyncx?= NXzUV2k3OjR{NESwNlM>
SGC-7901  MoHIRZBweHSxc3nzJGF{e2G7 NWTEOYNwOjBizszN M{TIS|I1KGh? M37rVYlvcGmkaYTzJGNRNW2nZHnheIVlKGGyb4D0c5Nqew>? MYWyOFI1OTN3MR?=
MG-63 M{DTdmZ2dmO2aX;uJGF{e2G7 NY\PVlZOOjBizszN M1rQTFAvPSCq NEW1ZoljdG:la4OgeIhmKEOKLXnu[JVk\WRicHjvd5Bpd3K7bHH0[YQhTUyNMTDwdo91\WmwIHX4dJJme3Orb36= M2S3ZlI1OjN7NkSw
ARPE-19 M4W2ZmZ2dmO2aX;uJGF{e2G7 Mo\UNlAh|ryP M4jYc|AvPSCq M1jQT4lvcGmkaYTzJGFx\Wyrbj3pcoR2[2WmIIDoc5NxcG:{eXzheIlwdiCxZjDFdosh[W6mIFHreC=> MV6yOFIzPzlzOB?=
CRL-2302 NHXKPFRHfW6ldHnvckBCe3OjeR?= MnzUNlAh|ryP NV:xRlltOC53IHi= MX\pcohq[mm2czDBdIVtcW5vaX7keYNm\CCyaH;zdIhwenmuYYTpc44hd2ZiRYLrJIFv\CCDa4S= M4Sw[FI1OjJ5OUG4
MCF-7 MlK3SpVv[3Srb36gRZN{[Xl? NGXCblczOCEQvF2= NEjzXo8yKGh? Ml7ZZYJwdGm|aHXzJIV5eHKnc4Ppc44hd2ZicHjvd5Bpd3K7bHH0[YQhTVKNIHPvMZRz\WG2bXXueEB4cXSqIHPvcop2\2G2ZR?= M1zkSVI1OjF4Mki5
MCF-7 M2DVT2Fxd3C2b4Ppd{BCe3OjeR?= MWCyNEDPxE1? NGq1bZgyKGh? NHzFbFFqdmO{ZXHz[ZMh[2G|cHHz[U06KGWweont[UBi[3Srdnn0fS=> MkPaNlQzOTZ{OEm=
DLD-1  NIHqeWNHfW6ldHnvckBCe3OjeR?= MmDxNlDDqM7:TR?= M{H3WlQ5KGh? MnmzdoVlfWOnczD0bIUhSk6LUEOg[ZhxemW|c3nvckBxemVvdILlZZRm\CC5aYToJFUu[XqjLXTD NFXaNm4zPDJzMUW4NS=>
HT-29 M2j5OWZ2dmO2aX;uJGF{e2G7 NVfzdHhxOjEEoN88US=> NXTrZplYPDhiaB?= NEfzblFz\WS3Y3XzJJRp\SCETlnQN{BmgHC{ZYPzbY9vKHC{ZT30doVifGWmIIfpeIghPS2jenGt[GM> M3LJd|I1OjFzNUix
7402 M1O4[GFxd3C2b4Ppd{BCe3OjeR?= MmjrN|Ah|ryP M{nRblUh\A>? NIP1UJhl\WO{ZXHz[ZMh[2WubDDwdo9tcW[ncnH0bY9v NF7NZ5IzPDJzMUK1Ny=>
7721 NXXNR4htSXCxcITvd4l{KEG|c3H5 NELaRmc{OCEQvF2= M4LET|Uh\A>? NWTyPGps\GWlcnXhd4V{KGOnbHygdJJwdGmoZYLheIlwdg>? MmT6NlQzOTF{NUO=
SGC7901  MWfBdI9xfG:|aYOgRZN{[Xl? M1fLZ|UxyqEQvF2= NFnNXpYzPC92OD:3NkBp NFLYVoNFVVOR NF;m[IZqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFrBT|Ihe2iUTlG= M3n5XlI1OTd6MkSw
SMMC7721 Mlf6SpVv[3Srb36gRZN{[Xl? M1S5OVI2NzVyIN88US=> MmXkNlQhcA>? NIflNFB{fXCycnXzd4V{KHSqZTDlfJBz\XO|aX;uJI9nKHBvQXv0JI9zKHBvRWLLNU8zyqB? MX:yOFE3QDB3Nh?=
MCF-7 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlSxNVAh|ryP MUK0PIg> MW\EUXNQ NWf1N2tnemW4ZYLz[ZMhSk6ILXnu[JVk\WRiY3XscEBkgWOuZTDhdpJme3R? MkPxNlQyPjN2MES=
Caco-2 M2PyOmZ2dmO2aX;uJGF{e2G7 MofDOVDDqM7:TR?= MlrTOFhp MmG2SG1UVw>? NXzOTXBx\W6qYX7j[ZMhfGinIH3SUmEhdGW4ZXzzJI9nyqCVQ17ONWEtTli\REOsxsBNS1RuwrDMU3gtyqCKSV[zRUzDqFqJMU[sxsBRTEV4QdMgZY5lyqCOR1HMV|E3yqCpZX7ld:Kh[29vdILlZZRm\CC5aYToJGRmgA>? MViyOFE3OTZ7NR?=
HAECs MUfGeY5kfGmxbjDBd5NigQ>? MYKxNEDPxE1? NUniO4x3OSCq MoWwxsBifHSnboXheIV{KFSQRj5OtU1{fGmvdXzheIVlKEmFQV2tNUBidmRiVlPBUU0yKGW6cILld5Nqd25? MmnzNlQyOzR4NUe=
Ca9-22 M13OTGZ2dmO2aX;uJGF{e2G7 MoHTN{DPxE1? NXXrSYduOSCq MmG0ZYJwdGm|aHXzJJRp\SCjYnnsbZR6KG:oIFjiVkB1dyCrbnT1Z4UhUUxvODDwdo9lfWO2aX;u NWnUPXdUOjRzMk[1N|I>
Ca9-22 NWnFNZNiTnWwY4Tpc44hSXO|YYm= NFKwU5A{KM7:TR?= MWWxM|IhcA>? MXry[YR2[2W|IFjiVk1qdmS3Y3XkJGFVTi1{IIDoc5NxcG:{eXzheIlwdg>? MYqyOFEzPjV|Mh?=
AGS M{nEVmZ2dmO2aX;uJGF{e2G7 MVSxNEDPxE4EoB?= MU[wMlUhcA>? NXjsN2hlcW6qaXLpeJMhfGinIIXwdoVofWyjdHnvckBw\iC2aHWgTWwuQCCpZX7l M13BV|I1OTB4MU[2
Caco-2  M{K3WWFxd3C2b4Ppd{BCe3OjeR?= M1PDSFExyqEQvF2= MXyyOOKhcA>? MWDk[YNz\WG|ZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTC1MWZW MXmyOFA6PTh4Mx?=
HCT-8 M4jBWmFxd3C2b4Ppd{BCe3OjeR?= MXOxNOKh|ryP MmHINlTDqGh? MkW5[IVkemWjc3XzJINmdGxiYYDvdJRwe2m|IHnu[JVk\WRiYomgOU1HXQ>? MoXoNlQxQTV6NkO=
A549 M2HtTGZ2dmO2aX;uJGF{e2G7 M3HpOVUxyqEQvF2= M3SzTVIhcA>? NULxeXFT[myxY3vzJGVTUyCyaH;zdIhwenmuYYTpc44hdWWmaXH0[YQh[nliMTyyMW5S MWKyOFA3Pzd{Nx?=
HPMC NGPt[mtHfW6ldHnvckBCe3OjeR?= MUSxNOKh|ryP MmPTOFghcA>? NHHV[Vdz\X[ncoPld{B1cGViY3jhcodmeyCrbjDj[YxtKG2xcoDoc4xw\3liaX7keYNm\CCkeTDIS3BFWw>? NXTVU3lvOjRyNEK4N|g>
HPMC NGG0V25CeG:ydH;zbZMhSXO|YYm= NEjyOJYyOMLizszN NVzib2hXOjUEoHi= NHLsd|Zz\X[ncoPld{Bl\WO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fUBqdmS3Y3XkJIJ6KEiJUFTT NIfFOoIzPDB2MkizPC=>
MGC803  MVnBdI9xfG:|aYOgRZN{[Xl? MnOxNlDDqM7:TR?= MmXsNUBp NITWVIFqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSCLRl6t{tHDqGGwZDC15qCzNUSIVWK= MmLFNlQxOjd5NUC=
SGC7901 NU\QVppvSXCxcITvd4l{KEG|c3H5 NW\3cmFkOjEEoN88US=> NHLLNVgyKGh? NGHrTJdqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSCLRl6t{tHDqGGwZDC15qCzNUSIVWK= MWOyOFAzPzd3MB?=
COLO205 MYfBdI9xfG:|aYOgRZN{[Xl? NWq2cIhMOTBxMkCvOFAh|ryP NHHhPFUzPCCq NYn4NWMzcW6mdXPld{BFVkFibHHk[IVzKG[xcn3heIlwdg>? M1z1cFI1ODF7MUC4
G292  NEPmTHBCeG:ydH;zbZMhSXO|YYm= M3LiN|MxyqEQvF2= MUSyJIg> NEjaRo1z\XO2b4Lld{Bk[XC|YXnjbY4ucW6mdXPl[EBk\WyuIHTlZZRp M2S3c|I1ODF{OUOw
BxPC-3 M2LXPGZ2dmO2aX;uJGF{e2G7 MW[xNEDPxE4EoB?= MWm2JIg> NVzmXZpZcW6lcnXhd4UhdWmULUG0N{BmgHC{ZYPzbY9v NHPYdZkzOzl5M{exNC=>
HPAF-II M2SyV2Z2dmO2aX;uJGF{e2G7 M161dVExKM7:TdMg NE\2V3U3KGh? MVLpcoNz\WG|ZTDtbXIuOTR|IHX4dJJme3Orb36= M{XvfVI{QTd|N{Gw
HL-60 M1ryNWFxd3C2b4Ppd{BCe3OjeR?= MoP2OVDDqM7:TR?= M{H3SVEhcA>? NIfwXnVz\XOldXXzJGJCOTR3IH3l[IlifGWmIHHwc5B1d3Orcx?= MYCyN|k1QDd3MR?=
HepG2 MmnmSpVv[3Srb36gRZN{[Xl? NYflfJJLPDBizszN NVPqNIxUPi9zMjDo NHHRdnNqdmirYnn0d{B1cGViaX7jdoVie2Vib3[gdE1GWktzIHHu[EBxNWNvSoXuJJBzd3SnaX6g[ZhxemW|c3nvckBjgSCSTB?= NVvne3lPOjN7NEK4OVE>
HUVECs M1XhUWZ2dmO2aX;uJGF{e2G7 Mlq5NlUh|ryP MXixJIg> NU\yOG5scW6lcnXhd4UhVkZvzsrCJJA3PSCwdXPs[YFzKHS{YX7zcI9k[XSrb36= NUK1[ZY5OjN7MEGwNFg>
LNCaP  NEPU[GRHfW6ldHnvckBCe3OjeR?= NEjSeVgyOCEQvF5CpC=> M{PzdVEhcA>? Mn6y[IVkemWjc3XzJJRp\SCHR1[geZBz\We3bHH0[YQheC2\Qj2x NV7BPFFJOjN6M{izNVg>
HL60  NXjEfHBmTnWwY4Tpc44hSXO|YYm= MlHlNlDDqM7:TR?= NV\uSW1UPzJiaB?= NVrrWI5ETE2VTx?= Mkn3bY5pcWKrdIOg[IF{[XSrbnniMYlv\HWlZXSgR2QyOWJiZYjwdoV{e2mxbh?= NITQbIwzOzh{NUW4OS=>
NB4  MoHCSpVv[3Srb36gRZN{[Xl? NEP3R5YyOCEQvF5CpC=> MVi3NkBp MYDEUXNQ MYjpcohq[mm2czDkZZNifGmwaXKtbY5lfWOnZDDDSFEy[iCneIDy[ZN{cW:w NV;YXFM2OjN6MkW1PFU>
EPOR/CR3 M1;LTmZ2dmO2aX;uJGF{e2G7 NVTVTHRWPTEEoN88US=> NFXETI4{KGh? NUnHR2ZbemWmdXPld{BGWE9iYX7kM49zKEmOLUOtbY5lfWOnZDD0bIUhfHm{b4PpcoUheGixc4Doc5J6dGG2aX;uxsA> M4\Q[FI{QDJyN{Ox
HUASMCs M37pemZ2dmO2aX;uJGF{e2G7 MnXWNVAh|ryPwrC= NIXSTWwzPCCq Mnzo[IlucW6rc3jld{BCdmdiSVmtZ4F2e2WmIGPPR3M{KG2UTlGgZY5lKHC{b4TlbY4h\XiycnXzd4lwdsLi NGPPfJYzOzhzNkS2PC=>
HUASMCs NXj3dWtNTnWwY4Tpc44hSXO|YYm= NGG3U4gyOCEQvF5CpC=> NEDJRlUzPCCq NH3CSpBqdmirYnn0d{BCdmdiSVmtbY5lfWOnZDDFVmsyNzJicHjvd5Bpd3K7bHH0bY9vKGyndnXs NUD5c3VCOjN6MU[0Olg>
SGC7901 M4nqSmZ2dmO2aX;uJGF{e2G7 MXmxNEDPxE4EoB?= Mlm3NlQhcA>? NGnOSlZqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kBxcG:|cHjvdplt[XSnZDDFVmsyNzJ? M4HkO|I{Pzl{NUi4
MKN45 M3XyRmZ2dmO2aX;uJGF{e2G7 NV\HfW9vOTBizszNxsA> MUeyOEBp NIf0OFhqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kBxcG:|cHjvdplt[XSnZDDFVmsyNzJ? M1LtdlI{Pzl{NUi4
SGC7901 NV70OIgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljHNVAh|ryPwrC= M33mfFI1NzR6L{eyJIg> NHyzSVRqdmirYnn0d{Bk\WyuIHfyc5d1cCClbz30doVifGWmIIfpeIghTEGSVB?= NInab5IzOzd7MkW4PC=>
MKN45 MojyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVGxNEDPxE4EoB?= MoDnNlQwPDhxN{KgbC=> MlLLbY5pcWKrdIOgZ4VtdCCpcn;3eIgh[29vdILlZZRm\CC5aYToJGRCWFR? MoDLNlM4QTJ3OEi=
SGC7901 MkXVRZBweHSxc3nzJGF{e2G7 NXSxXoxqOTBizszNxsA> MWKyOEBp M2HDRYlv[3KnYYPld{B1cGViRFHQWE1qdmS3Y3XkJINmdGxiYYDvdJRwe2m| M1T2WlI{Pzl{NUi4
MKN45 NVjzR4hXSXCxcITvd4l{KEG|c3H5 NYjWc5NFOTBizszNxsA> M3f5WVI1KGh? MYDpcoNz\WG|ZYOgeIhmKESDUGStbY5lfWOnZDDj[YxtKGGyb4D0c5Nqew>? NFLjemMzOzd7MkW4PC=>
BxPC-3 cells NYnCRlRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3L0NVIxyqEQvF2= MVWwMlUhcA>? NXXpbo1DcW6qaXLpeJMhXkWJRj3BMZJm\3WuYYTl[EBJXV[HQzDndo94fGhiYX7kJJR2[mViZn;ycYF1cW:wIHnu[JVk\WRiYomgVGFTNTJiQWC= NHTHb4szOzd4NEC0Oi=>
NB4  MXTBdI9xfG:|aYOgRZN{[Xl? NH3CVZEyOC9{MD:2NEDPxE1? NWrzNJFrOS53IHi= MY\EUXNQ NFvCTmRl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgZ48ufHKnYYTl[EB4cXSqIGDhZ4xqfGG6ZXy= NGXnOZAzOzd|NUW0NS=>
HepG2  M{PlXWZ2dmO2aX;uJGF{e2G7 Ml;MNlDDqM7:TR?= NFnxbVEzPCCq M371e4lvcGmkaYTzJJRp\SCKTz2xJJBzd3SnaX6g[ZhxemW|c3nvckBkdy22cnXheIVlKHerdHigcYV1\m:{bXnu MYWyN|cxPzZyOR?=
HUVECs MXfBdI9xfG:|aYOgRZN{[Xl? MYGyM|Qh|ryP MUKyOE81QCCq MmnFbY5lfWOnczDj[YxtKGSnYYTo NXjGUHI{OjN5MEe1NlA>
KG-1  MlHFRZBweHSxc3nzJGF{e2G7 MlrKNlDDqM7:TR?= NYHEUGw6OTJiaB?= NFW3b3NmdmijbnPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JHMy NVy1d|RKOjN5ME[2PVE>
AML 1# MmPnRZBweHSxc3nzJGF{e2G7 NUm2NGI4OjEEoN88US=> MX2xNkBp MnnD[Y5p[W6lZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDTNS=> NH\lbYszOzdyNk[5NS=>
A2780  MV7GeY5kfGmxbjDBd5NigQ>? Mn3HNlDDqM7:TR?= MofsNUBp MVficI9kc3NiRGTDSE1qdmS3Y3XkJGRTPSCneIDy[ZN{cW:w M{XBWlI{Pjl4OE[y

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
c-Jun / α-tubulin / p-ERK / ERK / p-AKT / AKT; 

PubMed: 17482134     


ERK regulates c-Jun levels in melanoma. The indicated melanoma cell lines were treated with 50μM PD98059 (PD) or 10μM LY294002 (LY) for 12h in the absence of serum. Protein samples were analyzed by Western blots using the indicated antibodies. α-Tubulin reveals equal loading.

p-JNK / JNK / Cyclin D1 ; 

PubMed: 17482134     


Inhibition of the MEK/ERK pathway affects c-Jun, P-JNK and cyclin D1 levels. The indicated melanoma cell lines were treated with 50μM PD98059 for 16h. Protein samples were analyzed by Western blots using the indicated antibodies. α-Tubulin reveals equal loading.

p-HER2 / HER2 ; 

PubMed: 24244023     


TE1cells were treated with wortmannin (Akt signal inhibitor), PD98059 (MAPK signal inhibitor), or lapatinib (EGFR and HER2 dual inhibitor) at the indicated doses or with DMSO as a negative control for 48 h. HER2-related signaling molecules were assessed by Western blot. 

MMP9 / XIAP / VEGF ; 

PubMed: 29695559     


SK-Hep1 cells were treated 10 μM PD98059 for 48 h.  Protein levels of MMP-9, XIAP, VEGF, cyclin-D1, and pERK were evaluated with western blotting assay.

17482134 24244023 29695559
In vivo Treatment of mice 30 minutes before focal cerebral ischemia with PD98059 protects against damage, resulting in a decrease in infarct volume. [5] Pretreated with PD98059 (10 mg/kg per i.v. injection) 30 minutes before and then together with hourly cerulein injections for 3 hours significantly ameliorates cerulein-induced acute pancreatitis ipancreatitis on the basis of pancreatic wet weight and histology. [6] Administration of PD98059 (10 mg/kg) in mice 1 hour after carrageenan causes a reduction in all the parameters of inflammation measured. [7]

Protocol

Kinase Assay:

[1]

- Collapse

In vitro MEK-inhibitory activity:

Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50 μL of 50 mM Tris, pH 7.4/10 mM MgCl2/2 mM EGTA/10 μM [γ-32P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE.
Cell Research:

[1]

- Collapse
  • Cell lines: K-Balb, KNRK, v-raf-3Y1, SRA/3Y1, EGFR/3T3, and K562
  • Concentrations: Dissolved in DMSO, final concentrations ~100 μM
  • Incubation Time: 3 dyas, or 7-10 days
  • Method:

    For monolayer growth, cells are plated into multi-well plates at 10,000-20,000/mL. Forty-eight hours later, various concentrations of PD98059 are added to the cell growth medium and incubation is continued for an additional 3 days. Cells are then removed from the wells by incubation with trypsin and enumerated with a Coulter Counter. For growth in soft agar, cells are seeded into 35-mm dishes at 5,000-10,000 cells per dish with growth medium containing 0.3% agar and desired concentrations of PD98059. After 7-10 days of growth, visible colonies are manually enumerated with the aid of a dissecting microscope.


    (Only for Reference)
Animal Research:

[7]

- Collapse
  • Animal Models: Male Sprague–Dawley rats with acute pancreatitis
  • Dosages: 10 mg/kg
  • Administration: Injection i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 14 mg/mL warmed (52.37 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
1mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 267.28
Formula

C16H13NO3

CAS No. 167869-21-8
Storage powder
in solvent
Synonyms N/A
Smiles COC1=C(N)C(=CC=C1)C2=CC(=O)C3=CC=CC=C3O2

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to formulate this inhibitor for i.p. injection?

  • Answer:

    You can prepare the stock by the vehicle 30% PEG400/0.5% Tween80/5% Propylene glycol, 0.5% CMC.

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products

Tags: buy PD98059 | PD98059 supplier | purchase PD98059 | PD98059 cost | PD98059 manufacturer | order PD98059 | PD98059 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID